IL117518A - The use of the product of aminotterlin to prepare a drug for the treatment of cardiovascular disease - Google Patents

The use of the product of aminotterlin to prepare a drug for the treatment of cardiovascular disease

Info

Publication number: IL117518A
Authority: IL; Israel
Prior art keywords: chf; pharmaceutical compositions; treatment; preparation; heart failure
Prior art date: 1995-03-17

Application number

IL11751896A

Other languages

English (en)

Hebrew (he)

Other versions

IL117518A0 (en

Original Assignee

Chiesi Farma Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-03-17

Filing date

1996-03-17

Publication date

2001-05-20

1996-03-17 Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa

1996-07-23 Publication of IL117518A0 publication Critical patent/IL117518A0/xx

2000-04-02 Priority to IL13541600A priority Critical patent/IL135416A0/xx

2001-05-20 Publication of IL117518A publication Critical patent/IL117518A/en

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 9
238000002360 preparation method Methods 0.000 title claims abstract description 8
238000011282 treatment Methods 0.000 title claims description 8
JRZGPXSSNPTNMA-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-1-amine Chemical class C1=CC=C2C(N)CCCC2=C1 JRZGPXSSNPTNMA-UHFFFAOYSA-N 0.000 title description 4
208000024172 Cardiovascular disease Diseases 0.000 title description 2
206010007559 Cardiac failure congestive Diseases 0.000 claims abstract description 18
206010019280 Heart failures Diseases 0.000 claims abstract description 18
238000002560 therapeutic procedure Methods 0.000 claims abstract description 15
208000019622 heart disease Diseases 0.000 claims abstract description 6
OMMYLOLVPCCZQZ-UHFFFAOYSA-N [6-(methylamino)-1-(2-methylpropanoyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl] 2-methylpropanoate Chemical compound C1=CC(OC(=O)C(C)C)=C(OC(=O)C(C)C)C2=C1CC(NC)CC2 OMMYLOLVPCCZQZ-UHFFFAOYSA-N 0.000 claims abstract description 3
150000003839 salts Chemical class 0.000 claims abstract 3
208000020446 Cardiac disease Diseases 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims 1
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 31
TWTMQRXNAZGSCE-UHFFFAOYSA-N hydron;[6-(methylamino)-1-(2-methylpropanoyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl] 2-methylpropanoate;chloride Chemical compound Cl.C1=CC(OC(=O)C(C)C)=C(OC(=O)C(C)C)C2=C1CC(NC)CC2 TWTMQRXNAZGSCE-UHFFFAOYSA-N 0.000 description 31
230000000694 effects Effects 0.000 description 20
MIMDMPWWTWVHFK-UHFFFAOYSA-N 6-(methylamino)-5,6,7,8-tetrahydronaphthalene-1,2-diol;hydrochloride Chemical compound Cl.C1=CC(O)=C(O)C2=C1CC(NC)CC2 MIMDMPWWTWVHFK-UHFFFAOYSA-N 0.000 description 19
150000001875 compounds Chemical class 0.000 description 19
229960003638 dopamine Drugs 0.000 description 15
102000005962 receptors Human genes 0.000 description 15
108020003175 receptors Proteins 0.000 description 15
239000003814 drug Substances 0.000 description 12
230000003291 dopaminomimetic effect Effects 0.000 description 10
230000000004 hemodynamic effect Effects 0.000 description 8
230000002093 peripheral effect Effects 0.000 description 8
230000009467 reduction Effects 0.000 description 8
241000700159 Rattus Species 0.000 description 7
229940079593 drug Drugs 0.000 description 7
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 6
239000005557 antagonist Substances 0.000 description 6
239000002934 diuretic Substances 0.000 description 6
229940030606 diuretics Drugs 0.000 description 6
238000001802 infusion Methods 0.000 description 6
239000000902 placebo Substances 0.000 description 6
229940068196 placebo Drugs 0.000 description 6
238000012360 testing method Methods 0.000 description 6
230000000747 cardiac effect Effects 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
238000001990 intravenous administration Methods 0.000 description 5
230000002182 neurohumoral effect Effects 0.000 description 5
230000004044 response Effects 0.000 description 5
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
208000001953 Hypotension Diseases 0.000 description 4
206010037368 Pulmonary congestion Diseases 0.000 description 4
230000004872 arterial blood pressure Effects 0.000 description 4
230000001077 hypotensive effect Effects 0.000 description 4
230000003518 presynaptic effect Effects 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
UCTWMZQNUQWSLP-UHFFFAOYSA-N Adrenaline Natural products CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 3
108060003345 Adrenergic Receptor Proteins 0.000 description 3
102000017910 Adrenergic receptor Human genes 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
229940102884 adrenalin Drugs 0.000 description 3
230000027455 binding Effects 0.000 description 3
150000003943 catecholamines Chemical class 0.000 description 3
210000003710 cerebral cortex Anatomy 0.000 description 3
208000027744 congestion Diseases 0.000 description 3
208000021822 hypotensive Diseases 0.000 description 3
230000006872 improvement Effects 0.000 description 3
-1 isobutyroyloxy-2-methylaminotetralin Chemical compound 0.000 description 3
230000036513 peripheral conductance Effects 0.000 description 3
230000036581 peripheral resistance Effects 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
230000002685 pulmonary effect Effects 0.000 description 3
230000009870 specific binding Effects 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
230000000304 vasodilatating effect Effects 0.000 description 3
230000024883 vasodilation Effects 0.000 description 3
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
208000032023 Signs and Symptoms Diseases 0.000 description 2
206010047139 Vasoconstriction Diseases 0.000 description 2
230000004913 activation Effects 0.000 description 2
210000004404 adrenal cortex Anatomy 0.000 description 2
230000001800 adrenalinergic effect Effects 0.000 description 2
230000036586 afterload Effects 0.000 description 2
239000000556 agonist Substances 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
230000008602 contraction Effects 0.000 description 2
239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
230000002526 effect on cardiovascular system Effects 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
210000005240 left ventricle Anatomy 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
238000000034 method Methods 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000002889 sympathetic effect Effects 0.000 description 2
210000001177 vas deferen Anatomy 0.000 description 2
230000025033 vasoconstriction Effects 0.000 description 2
BHDFPNRSDABMPW-UHFFFAOYSA-N 6-(methylamino)-5,6,7,8-tetrahydronaphthalene-1,2-diol Chemical compound C1=CC(O)=C(O)C2=C1CC(NC)CC2 BHDFPNRSDABMPW-UHFFFAOYSA-N 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
241000208011 Digitalis Species 0.000 description 1
229940098778 Dopamine receptor agonist Drugs 0.000 description 1
108090000371 Esterases Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
206010050394 Hyperkaliuria Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
208000004880 Polyuria Diseases 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000000674 adrenergic antagonist Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000002562 anti-bronchospastic effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
238000009530 blood pressure measurement Methods 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000001447 compensatory effect Effects 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
239000003218 coronary vasodilator agent Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000035619 diuresis Effects 0.000 description 1
FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
229960001253 domperidone Drugs 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
230000001435 haemodynamic effect Effects 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
230000035874 hyperreactivity Effects 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000297 inotrophic effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
230000036230 kaliuresis Effects 0.000 description 1
229960004145 levosulpiride Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000005226 mechanical processes and functions Effects 0.000 description 1
210000001640 nerve ending Anatomy 0.000 description 1
239000000712 neurohormone Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
238000011458 pharmacological treatment Methods 0.000 description 1
230000036316 preload Effects 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000004895 regional blood flow Effects 0.000 description 1
230000002040 relaxant effect Effects 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
239000007787 solid Substances 0.000 description 1
210000002563 splenic artery Anatomy 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
229960004940 sulpiride Drugs 0.000 description 1
230000008700 sympathetic activation Effects 0.000 description 1
210000002820 sympathetic nervous system Anatomy 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000002861 ventricular Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
General Chemical & Material Sciences (AREA)
Heart & Thoracic Surgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Vascular Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

IL11751896A 1995-03-17 1996-03-17 The use of the product of aminotterlin to prepare a drug for the treatment of cardiovascular disease IL117518A (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
IL13541600A IL135416A0 (en)	1995-03-17	2000-04-02	The use of an aminotetralin derivative in the preparation of pharmaceutical compositions for the treatment of cardiovascular diseases

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT95MI000532A IT1275935B1 (it)	1995-03-17	1995-03-17	Derivato di aminotetralina per la terapia di malattie cardiovascolari

Publications (2)

Publication Number	Publication Date
IL117518A0 IL117518A0 (en)	1996-07-23
IL117518A true IL117518A (en)	2001-05-20

Family

ID=11370947

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL11751896A IL117518A (en)	1995-03-17	1996-03-17	The use of the product of aminotterlin to prepare a drug for the treatment of cardiovascular disease

Country Status (31)

Country	Link
US (2)	US6013678A (de)
EP (2)	EP0814791B1 (de)
JP (1)	JPH11502211A (de)
KR (1)	KR100391143B1 (de)
CN (1)	CN1112920C (de)
AT (1)	ATE218856T1 (de)
AU (1)	AU702656B2 (de)
BR (1)	BR9607996A (de)
CA (1)	CA2215671A1 (de)
CZ (1)	CZ288488B6 (de)
DE (1)	DE69621786T2 (de)
DK (1)	DK0814791T3 (de)
EA (1)	EA000937B1 (de)
EE (1)	EE04040B1 (de)
ES (1)	ES2177769T3 (de)
HK (2)	HK1004802A1 (de)
HU (1)	HUP9801686A3 (de)
IL (1)	IL117518A (de)
IT (1)	IT1275935B1 (de)
LT (1)	LT4355B (de)
LV (1)	LV11882B (de)
MX (1)	MX9706971A (de)
NO (1)	NO317402B1 (de)
NZ (1)	NZ303993A (de)
PL (1)	PL183347B1 (de)
PT (1)	PT814791E (de)
SI (1)	SI9620036B (de)
SK (1)	SK282952B6 (de)
TR (1)	TR199700963T1 (de)
WO (1)	WO1996029065A2 (de)
ZA (1)	ZA962073B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2695157B2 (ja) *	1986-12-29	1997-12-24	松下電器産業株式会社	可変パイプラインプロセッサ
WO2000076544A1 (en) *	1996-03-13	2000-12-21	Chiesi Farmaceutici S.P.A.	Aminotetralin derivative for the therapy of cardiovascular diseases
EP1331004A3 (de) *	1999-06-09	2003-08-06	CHIESI FARMACEUTICI S.p.A.	Aminotetralin Derivat zur Behandlung von kardiovaskulären Erkrankungen
AU766230B2 (en) *	1999-06-09	2003-10-09	Chiesi Farmaceutici S.P.A.	Aminotetralin derivative for the therapy of cardiovascular diseases
IT1313583B1 (it) *	1999-07-30	2002-09-09	Chiesi Farma Spa	Derivati 2-amminotetralinici per la terapia del glaucoma.
IL152751A0 (en) *	2000-05-12	2003-06-24	Chiesi Farma Spa	Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them
SE0101854L (sv) *	2001-05-28	2002-11-29	Bioneris Ab	Användning av en förening med en negativt laddad region av grupper för behandling av restenos.
EP1384708A1 (de) *	2002-07-26	2004-01-28	CHIESI FARMACEUTICI S.p.A.	Verfahren zur Herstellung der Form I von Nolomirol Hydrochlorid
US20050101668A1 (en) *	2003-07-24	2005-05-12	Chiesi Farmaceutici S.P.A.	Aminotetralin derivatives as a medicament for the treatment and prevention of myocardial ischemic conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4134997A (en) *	1977-03-01	1979-01-16	University Of Iowa Research Foundation	Effect of an aminotetralin derivative on coronary blood flow in infarcted hearts
SU998342A1 (ru)	1981-12-11	1983-02-23	Предприятие П/Я А-3732	Способ получени синтетического цеолита типа @
IT1218322B (it) *	1982-06-10	1990-04-12	Chiesi Farma Spa	Derivati di 1,2,3,4-tetraidronaftalene,procedimento di preparazione e relative composizioni farmaceutiche

1995
- 1995-03-17 IT IT95MI000532A patent/IT1275935B1/it active IP Right Grant
1996
- 1996-03-13 JP JP8528045A patent/JPH11502211A/ja not_active Ceased
- 1996-03-13 WO PCT/EP1996/001060 patent/WO1996029065A2/en not_active Application Discontinuation
- 1996-03-13 NZ NZ303993A patent/NZ303993A/xx unknown
- 1996-03-13 HU HU9801686A patent/HUP9801686A3/hu unknown
- 1996-03-13 BR BR9607996A patent/BR9607996A/pt not_active Application Discontinuation
- 1996-03-13 TR TR97/00963T patent/TR199700963T1/xx unknown
- 1996-03-13 EP EP96907446A patent/EP0814791B1/de not_active Expired - Lifetime
- 1996-03-13 CA CA002215671A patent/CA2215671A1/en not_active Abandoned
- 1996-03-13 PT PT96907446T patent/PT814791E/pt unknown
- 1996-03-13 CZ CZ19972866A patent/CZ288488B6/cs not_active IP Right Cessation
- 1996-03-13 EP EP02001772A patent/EP1216702A3/de not_active Withdrawn
- 1996-03-13 AU AU51072/96A patent/AU702656B2/en not_active Ceased
- 1996-03-13 DE DE69621786T patent/DE69621786T2/de not_active Expired - Fee Related
- 1996-03-13 SI SI9620036A patent/SI9620036B/sl not_active IP Right Cessation
- 1996-03-13 AT AT96907446T patent/ATE218856T1/de not_active IP Right Cessation
- 1996-03-13 MX MX9706971A patent/MX9706971A/es not_active IP Right Cessation
- 1996-03-13 ES ES96907446T patent/ES2177769T3/es not_active Expired - Lifetime
- 1996-03-13 EA EA199700243A patent/EA000937B1/ru not_active IP Right Cessation
- 1996-03-13 US US08/913,363 patent/US6013678A/en not_active Expired - Fee Related
- 1996-03-13 KR KR1019970706438A patent/KR100391143B1/ko not_active IP Right Cessation
- 1996-03-13 CN CN96193312A patent/CN1112920C/zh not_active Expired - Fee Related
- 1996-03-13 EE EE9700231A patent/EE04040B1/xx not_active IP Right Cessation
- 1996-03-13 SK SK1254-97A patent/SK282952B6/sk unknown
- 1996-03-13 PL PL96322284A patent/PL183347B1/pl not_active IP Right Cessation
- 1996-03-13 DK DK96907446T patent/DK0814791T3/da active
- 1996-03-14 ZA ZA962073A patent/ZA962073B/xx unknown
- 1996-03-17 IL IL11751896A patent/IL117518A/en not_active IP Right Cessation
1997
- 1997-09-15 LV LVP-97-166A patent/LV11882B/en unknown
- 1997-09-15 LT LT97-147A patent/LT4355B/lt not_active IP Right Cessation
- 1997-09-16 NO NO19974267A patent/NO317402B1/no not_active IP Right Cessation
1998
- 1998-05-12 HK HK98104093A patent/HK1004802A1/xx not_active IP Right Cessation
1999
- 1999-06-09 US US09/328,434 patent/US6103760A/en not_active Expired - Fee Related
2002
- 2002-12-19 HK HK02109206.9A patent/HK1048060A1/zh unknown

Also Published As

Publication number	Publication date
JPH11502211A (ja)	1999-02-23
AU5107296A (en)	1996-10-08
PT814791E (pt)	2002-10-31
LV11882B (en)	1998-03-20
DK0814791T3 (da)	2002-10-07
SK125497A3 (en)	1998-02-04
MX9706971A (es)	1997-11-29
HUP9801686A2 (hu)	1999-06-28
SI9620036A (sl)	1998-02-28
EE9700231A (et)	1998-04-15
PL183347B1 (pl)	2002-06-28
NO317402B1 (no)	2004-10-25
KR100391143B1 (ko)	2003-11-28
IT1275935B1 (it)	1997-10-24
CZ286697A3 (cs)	1998-03-18
CN1181699A (zh)	1998-05-13
LT4355B (lt)	1998-06-25
HK1004802A1 (en)	1998-12-11
ES2177769T3 (es)	2002-12-16
CN1112920C (zh)	2003-07-02
AU702656B2 (en)	1999-02-25
NZ303993A (en)	2000-12-22
US6103760A (en)	2000-08-15
HK1048060A1 (zh)	2003-03-21
LT97147A (en)	1998-02-25
EP0814791B1 (de)	2002-06-12
EP1216702A2 (de)	2002-06-26
EP0814791A1 (de)	1998-01-07
TR199700963T1 (xx)	1998-02-21
EP1216702A3 (de)	2002-09-04
ATE218856T1 (de)	2002-06-15
CZ288488B6 (en)	2001-06-13
ZA962073B (en)	1996-11-27
NO974267L (no)	1997-11-07
LV11882A (lv)	1997-12-20
ITMI950532A1 (it)	1996-09-17
US6013678A (en)	2000-01-11
ITMI950532A0 (it)	1995-03-17
SI9620036B (sl)	2002-10-31
HUP9801686A3 (en)	1999-10-28
WO1996029065A2 (en)	1996-09-26
SK282952B6 (sk)	2003-01-09
EE04040B1 (et)	2003-06-16
EA199700243A1 (ru)	1998-02-26
CA2215671A1 (en)	1996-09-26
NO974267D0 (no)	1997-09-16
EA000937B1 (ru)	2000-06-26
WO1996029065A3 (en)	1996-11-28
KR19980703030A (ko)	1998-09-05
BR9607996A (pt)	1998-06-23
DE69621786D1 (de)	2002-07-18
IL117518A0 (en)	1996-07-23
PL322284A1 (en)	1998-01-19
DE69621786T2 (de)	2003-01-02

Legal Events

Date	Code	Title
2001-10-31	FF	Patent granted
2001-11-25	KB	Patent renewed
2002-05-23	KB	Patent renewed
2006-12-07	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
EP0814791B1 (de)	2002-06-12	Aminotetralinderivat zur behandlung von herzkreislauferkrankung
Liard	1994	L-NAME antagonizes vasopressin V2-induced vasodilatation in dogs
US7402611B1 (en)	2008-07-22	Use of amino acids for making medicines for treating to insulin-resistance
Om	1992	Cardiovascular complications of ***e
AU766230B2 (en)	2003-10-09	Aminotetralin derivative for the therapy of cardiovascular diseases
Nademanee	1992	Cardiovascular effects and toxicities of ***e
Aronson et al.	1991	Effects of fenoldopam on renal blood flow and systemic hemodynamics during isoilurane anesthesia
WO2000076544A1 (en)	2000-12-21	Aminotetralin derivative for the therapy of cardiovascular diseases
JP2001507006A (ja)	2001-05-29	糖尿病性血管機能不全の予防のための薬剤の製造へのｃｏｍｔ阻害剤の使用
EP1331004A2 (de)	2003-07-30	Aminotetralin Derivat zur Behandlung von kardiovaskulären Erkrankungen
Bevan et al.	1992	P. Fernyhough, LT Diemel, WJ Smith & DR Tomlinson, Department of Pharmacology, Queen Mary and Westfield College, Mile End Road, London El 4NS. Neuropeptide gene expression in sensoryneurones is regulated by the classic neurotrophic factor, nerve growth factor (NGF).
Bevan et al.	0	P. Fernyhough, LT Diemel, WJ Smith & DR Tomlinson, Department of Pharmacology, Queen Mary and Westfield College, Mile End Road, London El 4NS. Neuropeptide gene expression in sensoryneurones is regulated by the classic neurotrophic factor, nerve growth factor (NGF).
Manolis et al.	1996	4 Cardiovascular Agents
KR20020045552A (ko)	2002-06-19	만성 폐색성 폐질환의 치료 방법